MedTrace Logo

Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

NCT01307501 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-07-19

Study results available
· View outcomes & findings →

Summary

ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.

Conditions

  • Metastatic Lung Cancer

Interventions

DEVICE

Cryoablation

Application of extremely cold temperatures to the identified tumor(s).

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Hiran Fernando, MD · Boston Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-04
Primary Completion
2018-08-30
Completion
2018-08-30
FDA Device
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01307501 on ClinicalTrials.gov